Theresa Evans, APRN
Nurse Practitioner · Council Bluffs, IANPI 1477012029
Payments from drug & device makers
Across 125 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$292
- Pfizer$250
- Genentech USA, Inc.$172
- Sanofi$163
- AbbVie$137
- Johnson & Johnson$135
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,42096%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $292 |
| Pfizer | 20 | $250 |
| Genentech USA, Inc. | 7 | $172 |
| Sanofi | 6 | $163 |
| AbbVie | 6 | $137 |
| Johnson & Johnson | 4 | $135 |
| Bristol Myers Squibb | 7 | $123 |
| Exelixis Inc. | 2 | $122 |
| Array Biopharma Inc | 7 | $107 |
| E.r. Squibb & Sons, L.L.C. | 6 | $102 |
| AstraZeneca | 4 | $93 |
| EMD Serono, Inc. | 3 | $70 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Servier Pharmaceuticals LLC | 3 | $60 |
| Gilead | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Merck | 2 | $44 |
| Eisai Inc. | 2 | $41 |
| Pharmaessentia USA Corporation | 2 | $39 |
| Incyte Corporation | 2 | $34 |
| Stemline Therapeutics Inc. | 2 | $32 |
| Karyopharm Therapeutics Inc. | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 2 | $30 |
| Mirati Therapeutics, Inc. | 1 | $25 |
| Immunogen, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Pharmaand GmbH | 1 | $19 |
| Tolmar, Inc. | 1 | $19 |
| Aadi Bioscience, Inc. | 1 | $18 |
| Geron Corporation | 1 | $18 |
| Novocure Inc. | 1 | $18 |
| Coherus Oncology, Inc. | 1 | $16 |
| Caris MPI, Inc. | 1 | $16 |
How this compares
$2,519 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 14 | $4,737 |
| Anastrozole | 118 | $1,887 |
| Prochlorperazine Maleate | 55 | $561 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $506 |
| Ondansetron OdtOndansetron | 35 | $500 |
| Letrozole | 46 | $465 |
| Hydroxyurea | 20 | $458 |
| Morphine Sulfate ErMorphine Sulfate | 16 | $417 |
| Oxycodone Hcl | 24 | $374 |
| Ondansetron Hcl | 34 | $325 |
| Dexamethasone | 11 | $203 |
| LoperamideLoperamide Hcl | 12 | $146 |
| Prednisone | 23 | $99 |
| Alendronate Sodium | 13 | $74 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Council Bluffs
- Marcella SorrellCouncil Bluffs$7K
- Tara SandsCouncil Bluffs$4K
- Lauren WarnekeCouncil Bluffs$3K
- Nicole MorganDes Moines$106K
- Julie CoffeyIowa City$31K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
- Beth ChiaWest Des Moines$15K
- Margaret KinneyRed Oak$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.